Heterogeneity in cancer guidelines: should we eradicate or tolerate? (2008)
Pentheroudakis, G., Stahel, R., Hansen, H., Pavlidis, N.
Background: Heterogeneity in aspects of development, structure and context of oncology guidelines was not evaluated. We analysed and critically examined its implications. Materials and methods: Nine...
Papaxoinis, G., Fountzilas, G., Rontogianni, D., Dimopoulos, M. A., Pavlidis, N., Tsatalas, C., ...
Background: The aim was to examine characteristics and treatment results of patients with mucosa-associated lymphoid tissue (MALT) non-Hodgkin's lymphomas. Patients and methods: Epidemiological and...
Fountzilas, G., Papakostas, P., Dafni, U., Makatsoris, T., Karina, M., Kalogera-Fountzila, A., ...
Background: The prognosis of patients with recurrent and/or metastatic head and neck cancer (HNC) is poor. Median survival of these patients following chemotherapy is in the range of 6 to 9 months....
Fountzilas, G, Papakostas, P, Dafni, U, Makatsoris, T, Karina, M, Kalogera-Fountzila, A, ...
Background: The prognosis of patients with recurrent and/or metastatic head and neck cancer (HNC) is poor. Median survival of these patients following chemotherapy is in the range of 6 to 9 months....
Fountzilas, G., Papakostas, P., Dafni, U., Makatsoris, T., Karina, M., Kalogera-Fountzila, A., ...
Background: The prognosis of patients with recurrent and/or metastatic head and neck cancer (HNC) is poor. Median survival of these patients following chemotherapy is in the range of 6 to 9 months....
Aravantinos, G., Fountzilas, G., Kosmidis, P., Dimopoulos, M. A., Stathopoulos, G. P., Pavlidis, N., ...
Background: We compared the combination plus Carboplatin plus paclitaxel, which is considered the treatment of choice for initial chemotherapy of advanced ovarian cancer (AOC) with a regimen...
Pentheroudakis, G., Pavlidis, N.
Despite unique tumour epidemiology, a higher cancer incidence and modest survival improvement compared to paediatric patients, adolescents and young adults aged 15–30 have not been considered as a...
Aravantinos, G., Fountzilas, G., Kosmidis, P., Dimopoulos, M. A., Stathopoulos, G. P., Pavlidis, N., ...
Background: We compared the combination plus Carboplatin plus paclitaxel, which is considered the treatment of choice for initial chemotherapy of advanced ovarian cancer (AOC) with a regimen...
Briasoulis, E., Pentheroudakis, G., Karavasilis, V., Tzamakou, E., Rammou, D., Pavlidis, N.
Background: We aimed to define the maximum tolerated dose (MTD) and characterize the toxicity of the combination of pegylated liposomal doxorubicin (PLD; Caelyx™) and weekly paclitaxel (wPTX), and...
Aravantinos, G., Bafaloukos, D., Fountzilas, G., Christodoulou, C., Papadimitriou, C., Pavlidis, N., ...
Background: This multicenter, prospective phase II study evaluated the safety and efficacy of the combination of docetaxel and vinorelbine in patients with platinum-resistant, paclitaxel-pretreated...
Skarlos, D.V., Samantas, E., Briassoulis, E., Panoussaki, E., Pavlidis, N., Kalofonos, H. P., ...
Background Concurrent platinum-etoposide chemotherapy given in combination with hyperfractionated thoracic radiation therapy (HTRT) in limited disease (LD) small cell lung cancer (SCLC) is...
Bamias, A., Baltayiannis, G., Kamina, S., Fatouros, M., Lymperopoulos, E., Agnanti, N., ...
Metastatic involvement of the gastrointestinal (GI) tract secondary to breast cancer is rare. Reported herein is the case of a 74-year-old woman with metastatic lobular breast carcinoma to the rectum...
Aravantinos, G., Dimopoulos, M. A., Kosmidis, P., Bafaloukos, D., Papadimitriou, C., Kiamouris, C., ...
Background: The prognosis of platinum resistant ovarian cancer is very poor and the treatment of choice has not been clearly defined. Patients and methods: We conducted a phase II study with the...
Fountzilas, G., Stathopoulos, G., Nicolaides, C., Kalogera-Fountzila, A., Kalofonos, H., Nikolaou, A., ...
Background: Paclitaxel as monotherapy or in combination with other drugs has demonstrated significant activity in patients with squamous cell carcinoma of the head and neck region (SCCHN)....
Fountzilas, G., Zisiadis, A., Dafni, U., Konstantaras, C., Hatzitheoharis, G., Liaros, A., ...
Background: Randomized studies have shown that postoperative chemotherapy with or without radiation therapy (RT) improved local control and survival of patients with stages II or III rectal cancer....
Briasoulis, E., Karavasilis, V., Anastasopoulos, D., Tzamakou, E., Fountzilas, G., Rammou, D., ...
Background: Docetaxel is an agent with impressive clinical activity but a rather poor profile of toxicity when given every three weeks. Therefore, optimisation of its clinical use is highly...
Fountzilas, G., Papadimitriou, C., Kalogera-Fountzila, A., Aravantinos, G., Bafaloukos, D., ...
Purpose: To evaluate the activity and toxicity of the combination of paclitaxel given by three-hour infusion, and carboplatin as first-line chemotherapy in patients with advanced breast cancer (ABC)....
Fountzilas, G., Athanassiades, A., Giannakakis, T., Briasoulis, E., Bafaloukos, D., Kalogera-Fountzila, A., ...
Purpose To evaluate the impact on the response rate in patients with advanced breast cancer (ABC) of the doubling of the dose intensity (DI) of epirubicin monotherapy. Patients and methods From...
Fountzilas, G., Skarlos, D., Athanassiades, A., Kalogera-Fountzila, A., Samantas, E., ...
Background: Paclitaxel has been demonstrated to have significant activity in recurrent or metastatic head and neck cancer (HNC). In addition, the combination of paclitaxel and cisplatin is active in...
Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study (1997)
Kosmidis, P. A., Mylonakis, N., Fountzilas, G., Samantas, E., Athanasiadis, A., Andreopoulou, E., ...
Background Based on the high activity of single-agent paclitaxel and the superior one-year survival rates of patients with non-small-cell lung cancer (NSCLC) treated with carboplatin, a phase II...
Multicentre phase II pharmacological evaluation of rhizoxin (1996)
Verweij, J., Aamdal, S., Wagener, D.J.T., Heinrich, B., Pavlidis, N., ...
Kosmidis, P., Mylonakis, N., Fountzilas, G., Pavlidis, N., Samantas, E., Karabelis, A., ...
Background: It was recently reported that when ifosfamide was added to cisplatin and vinblastine the response rate was increased but not the survival in patients with non-small-cell lung cancer...
Pavlidis, N., Hanauske, A. R., Gamucci, T., Smyth, J., Lehnert, M., Velde, A. Te, ...
In a multicentre randomized trial of the EORTC-ECSG, we have treated 38 chemotherapy naïve patients with advanced non-small-cell lung cancer (NSCLC) with EO9, a novel bio-reductive alkylating...
Phase II clinical trials with rhizoxin in breast cancer and melanoma (1996)
Catimel, G., Aamdal, S., Pavlidis, N., ...
Verweij, J., Wanders, J., Nielsen, A. L., Pavlidis, N., Calabresi, F., Huinink, W. Ten Bokkel, ...
Purpose: To test the antitumor activity of Elsamitrucin in metastatic cancer of the breast, colon and rectum, non-small cell lung and ovary. Patients and methods: Eligibility required histologically...
Skarlos, D. V., Samantas, E., Kosmidis, P., Fountzilas, G., Angelidou, M., Palamidas, Ph., ...
Purpose: To compare the efficacy and toxicity of etoposide and cisplatin (EP) with etoposide and carboplatin (EC) in combination with irradiation in small-cell lung cancer (SCLC). Methods: Previously...
Pavlidis, N., Kosmidis, P., Skarlos, D., Briassoutis, E., Beer, M., Theoharis, D., ...
In this retrospective analysis 48 patients with metastatic undifferentiated carcinoma, adenocarcinoma and epidermoid carcimona of unknown origin were studied. The purpose of this analysis was to...
Koutsilieris, M., Reyes-Moreno, C., Choki, I., Sourla, A., Doillon, C., Pavlidis, N.
One-third of women with breast cancer will develop bone metastases and eventually die from disease progression at these sites. Therefore, we analyzed the ability of human MG-63 osteoblast-like cells...
Cerny, T., Kaplan, S., Pavlidis, N., Schöffski, P., Epelbaum, R., Van Meerbeek, J., ...
In a multicentre trial of the EORTC ECTG we have treated 43 non-pretreated patients with advanced non-small-cell lung cancer (NSCLC) with the new semisynthetic taxoid docetaxel (Taxotere). Six...
Hanauske, A. R., Catimel, G., Aamdal, S., Paridaens, R., Pavlidis, N., ...
Rhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. It has shown broad activity against murine tumour models and is also active against vinca...
Kaplan, S., Hanauske, A. R., Pavlidis, N., Bruntsch, U., Te Velde, A., Wanders, J., ...
In a multicentre trial of the EORTC-Early Clinical Trials Group (ECTG) we treated 31 chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) with rhizoxin, a novel...
McLeod, H. L., Murray, L. S., Wanders, J., Setanoians, A., Graham, M. A., Pavlidis, N., ...
Rhizoxin is a macrocyclic lactone compound that binds to tubulin and inhibits microtubule assembly. Rhizoxin demonstrated preclinical anti-tumour activity against a variety of human tumour cell lines...
Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation
Minas, V, Rolaki, A, Kalantaridou, S N, Sidiropoulos, J, Mitrou, S, Petsas, G, ...
Although corticotropin-releasing hormone (CRH) and Fas ligand (FasL) have been documented in ovarian carcinoma, a clear association with tumour progression and immuno-escape has not been established....